


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**COMPLETION OF ALL PARTICIPANTS ENROLLMENT IN THE PHASE III
REGISTRATIONAL CLINICAL TRIAL OF TQC2731 INJECTION “TSLP
MONOCLONAL ANTIBODY” FOR CHRONIC SINUSITIS WITH NASAL POLYPS**

The Board of Directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that a Phase III registrational clinical trial of TQC2731 Injection “TSLP Monoclonal Antibody,” a national Category 1 innovative drug independently developed by Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Group, for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) has recently completed the enrollment of all participants.

TQC2731 is a humanised monoclonal antibody targeting thymic stromal lymphopoietin (TSLP). TSLP is an epithelial cell-derived cytokine produced during pro-inflammatory stimuli (such as infectious, allergic, and environmental stimuli) and trauma responses^[1] and serves as an “upstream signal” that initiates the inflammatory response. Upon binding to the TSLP receptor (TSLPR) on the cell surface, TSLP promotes the activation of Th2 inflammatory cells and the expression of various inflammatory cytokines, including IL-4, IL-5, and IL-13; simultaneously, TSLP can also enhance Th17 responses by influencing neutrophil function, thereby participating in non-type 2 inflammation^[2]. Therefore, blocking TSLP can inhibit inflammatory initiation signals upstream in the inflammatory cascade, reduce the release of downstream inflammatory factors, and exert anti-inflammatory effects.

CRSwNP is one of the major phenotypes of chronic rhinosinusitis (CRS) and imposes a heavier clinical burden than chronic rhinosinusitis without nasal polyps (CRSsNP). Its cardinal symptoms include persistent nasal congestion, hyposmia and purulent nasal discharge; it is often accompanied by asthma, is prone to recurrent episodes, and severely impacts the patient’s quality of life^[3]. The current gold standard for CRSwNP is intranasal corticosteroids as the cornerstone of medical therapy, combined with endoscopic surgery; however, postoperative recurrence rates remain as high as 35%–60%. CRS is classified into Type 2 and non-Type 2 inflammation based on immunophenotype. Most currently

marketed biologics target Type 2 inflammation and have limited efficacy in patients with non-Type 2 inflammation, resulting in a significant unmet medical need. By antagonising TSLP, TQC2731 has the potential to modulate both Type 2 and non-Type 2 inflammation, offering differentiated development potential across a broader spectrum of inflammatory phenotypes.

In addition to CRSwNP, a Phase III registrational clinical trial of TQC2731 for severe asthma is currently underway. As the first domestically developed TSLP monoclonal antibody to enter Phase III clinical trials, TQC2731 is expected to provide new treatment options for more patients with Type 2 and non-Type 2 inflammation.

Sources:

- [1] Varricchi Gilda, Pecoraro Antonio, Marone Giancarlo et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. [J]. Front Immunol, 2018, 9: 1595.
- [2] De Corso, E., Hellings, P.W., Fokkens, W.J. et al. Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps. Curr Allergy Asthma Rep 25, 7 (2025)
- [3] Rhinology Group of the Editorial Board of the Chinese Journal of Otolaryngology-Head and Neck Surgery; Rhinology Group of the Otolaryngology-Head and Neck Surgery Branch of the Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Chronic Sinusitis (2024) [J]. Chinese Journal of Otolaryngology-Head and Neck Surgery, 2025, 60(3): 221–249. DOI: 10.3760/cma.j.cn115330-20250116-00051.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 21 October 2026

As at the date of this announcement, the Board of the Company comprises five executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive Directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.